10-Q: Exelixis Reports Strong Product Revenue Growth and Positive Zanzalintinib Trial Results, Driving Earnings Higher

Exelixis announced robust product revenue growth, positive Phase 3 results for zanzalintinib in colorectal cancer, and new regulatory approvals for CABOMETYX, alongside ongoing share repurchases.

Summary

• Net product revenues increased by 27% to $1.03 billion for the six months ended June 30, 2025, driven by strong CABOMETYX sales.
• Total revenues for the six months ended June 30, 2025, were $1.12 billion, a 6% increase year-over-year, despite a 63% decrease in collaboration revenues due to a non-recurring milestone payment in the prior year.
• Net income surged by 31% to $344.5 million, with diluted earnings per share rising 36% to $1.20 for the six-month period.
• Operating income increased by 31% to $400.4 million for the six months ended June 30, 2025.
• Positive top-line results from the STELLAR-303 Phase 3 trial showed a statistically significant improvement in overall survival for zanzalintinib in combination with atezolizumab in metastatic, refractory non-MSI-H/dMMR colorectal cancer, with an intent to file a New Drug Application in the U.S.
• The FDA approved CABOMETYX for previously treated advanced neuroendocrine tumors (NET) in March 2025, and Ipsen received European Commission approval for CABOMETYX in NET in July 2025.
• The company repurchased $796.3 million of common stock as of June 30, 2025, under its $1 billion authorization, with $203.7 million remaining.
• A settlement agreement was reached with Biocon in July 2025, allowing Biocon to market a generic version of CABOMETYX in the U.S. starting January 1, 2031, subject to FDA approval.
• The "One Big Beautiful Bill Act," signed July 4, 2025, permanently repeals the requirement to capitalize domestic R&E expenditures for federal income tax purposes for taxable years beginning after December 31, 2024, providing an estimated federal cash tax benefit of $147 million.

Sentiment

Score: 7

Explanation: The company demonstrated strong product revenue growth and significant increases in net income and EPS. Positive Phase 3 results for zanzalintinib in a key indication (colorectal cancer) and new regulatory approvals for CABOMETYX are strong catalysts. While collaboration revenues declined due to a non-recurring milestone, the underlying operational performance is robust. Ongoing share repurchases and a favorable tax law change further enhance shareholder value. The ongoing ANDA litigations present a long-term risk, but the Biocon settlement provides some clarity.

Positives

• Net product revenues increased by 27% to $1.03 billion for the six months ended June 30, 2025, primarily driven by CABOMETYX.
• CABOMETYX sales volume increased by 20% and 22% for the three and six months ended June 30, 2025, respectively, reflecting continued demand and market share gains.
• Net income increased by 31% to $344.5 million for the six months ended June 30, 2025.
• Diluted EPS increased by 36% to $1.20 for the six months ended June 30, 2025.
• Income from operations increased by 31% to $400.4 million for the six months ended June 30, 2025.
• Net cash provided by operating activities increased by 38% to $260.4 million for the six months ended June 30, 2025.
• Positive top-line results from the STELLAR-303 Phase 3 trial for zanzalintinib in colorectal cancer demonstrated a statistically significant improvement in overall survival, with plans to file a New Drug Application in the U.S.
• FDA approval of CABOMETYX for previously treated advanced neuroendocrine tumors (NET) in March 2025 expands market opportunities.
• European Commission approval for CABOMETYX in NET in EEA, Brazil, and Australia in July 2025 further expands international market access.
• The "One Big Beautiful Bill Act" provides an estimated $147 million federal cash tax benefit by repealing the capitalization of domestic R&E expenditures.
• Ongoing share repurchase program, with $796.3 million repurchased as of June 30, 2025, demonstrates commitment to shareholder returns.
• Settlement with Biocon provides clarity on generic entry for CABOMETYX in the U.S. starting January 1, 2031.
• Advancement of pipeline candidates with new IND acceptance for XB371 and initiation of Phase 1 study for XB628.

Negatives

• Collaboration revenues decreased significantly by 63% to $90.4 million for the six months ended June 30, 2025, primarily due to a $150.0 million commercial milestone payment from Ipsen in the prior year period that did not recur.
• Net decrease in cash and cash equivalents of $52.9 million for the six months ended June 30, 2025, primarily due to share repurchases.
• Total cash, cash equivalents, and marketable securities decreased by 21% from $1.75 billion at December 31, 2024, to $1.39 billion at June 30, 2025.
• Strategic decision not to proceed to Phase 3 for STELLAR-305 (zanzalintinib in SCCHN) due to emerging data and competitive landscape.
• Ongoing ANDA litigation with MSN and Sun Pharmaceutical Industries Ltd. for generic CABOMETYX, which could significantly decrease U.S. revenues if successful.
• COMETRIQ net product revenues decreased by 29% to $4.5 million for the six months ended June 30, 2025.

Risks

• Ability to generate sufficient cash flow depends on the continued commercial success of CABOMETYX in highly competitive indications.
• Uncertainty that clinical trials for additional indications will demonstrate adequate safety and efficacy to receive regulatory approval.
• Challenges in effectively commercializing CABOMETYX for additional indications even if approved.
• Difficulty in obtaining and maintaining coverage and reimbursement for CABOMETYX from private third-party and government payers.
• Impact of healthcare policy changes in the U.S., including increased drug discounts under the Medicare Part D Manufacturer Discount Program and potential tariffs on imported pharmaceuticals.
• Maintaining a competitive position in the shifting landscape of therapeutic strategies for cancer treatment.
• Potential competition from generic or other versions of marketed products, specifically CABOMETYX, from ANDAs filed by MSN, Sun, and Azurity, which could materially harm business, financial condition, and results of operations.
• Challenges of scaling the organization to meet demands of expanded drug development.
• Unanticipated delays in clinical testing.
• Inherent risks and uncertainties associated with drug discovery operations, especially globally.
• Unsuccessful discovery of new potential cancer treatments or identification of appropriate candidates for in-licensing or acquisition.

Future Outlook

Expects net product revenues to increase for the remainder of 2025, driven by the recent FDA approval of CABOMETYX for previously treated advanced NET and continued demand for CABOMETYX in combination with nivolumab. Projects collaboration services revenues may decrease for the remainder of 2025 due to lower development cost reimbursements and increased royalty payments. Anticipates clinical trial costs to increase for the remainder of 2025, primarily due to various zanzalintinib, XL309, XB371, XB628, and XB010 studies. Overall research and development expenses are projected to increase for the remainder of 2025. Selling, general and administrative expenses are also expected to increase due to stock-based compensation and personnel expenses. The company plans to progress up to two new development candidates into preclinical development later in 2025 and continue pipeline expansion initiatives.

Management Comments

• "We continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline."
• "We project our net product revenues may increase for the remainder of 2025, as compared to the corresponding prior year period, as a result of the FDAs approval in the first quarter of 2025, of CABOMETYX for patients with previously treated advanced NET and for similar reasons noted above."
• "We project that clinical trial costs may increase for the remainder of 2025, as compared to the corresponding prior year period, primarily driven by higher costs associated with various studies evaluating zanzalintinib, and the XL309, XB371, XB628 and XB010 studies, partially offset by lower costs associated with studies evaluating cabozantinib and XB002."
• "To continue growing our pipeline, we are prioritizing investment in new molecules that are clinically differentiated with the potential to improve the standard of care for our cancer patients, including current and planned clinical trial programs evaluating zanzalintinib, XL309, XB010, XB371, and XB628."
• "As of the date of this Quarterly Report on Form 10-Q, we expect to progress up to two new development candidates into preclinical development later in 2025."

Industry Context

The company operates in the highly competitive oncology market, focusing on next-generation medicines and combination regimens. Its flagship product, CABOMETYX, is a key player in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and neuroendocrine tumors (NET), competing with and complementing immune checkpoint inhibitors (ICIs). The strategic decision to discontinue the Phase 3 portion of STELLAR-305 in SCCHN reflects the dynamic and competitive nature of specific cancer indications, where emerging data and alternative commercial opportunities influence development priorities. The company's focus on zanzalintinib, a novel TKI, and expansion into biotherapeutics like ADCs and bispecific antibodies, aligns with broader industry trends towards targeted therapies and diverse modalities to address unmet needs in cancer treatment. The impact of the Inflation Reduction Act and Medicare Part D Manufacturer Discount Program highlights the increasing regulatory and pricing pressures faced by pharmaceutical manufacturers in the U.S.

Comparison to Industry Standards

• The company's strategy of combining its flagship molecule, cabozantinib, with immune checkpoint inhibitors (ICIs) like nivolumab (OPDIVO from Bristol-Myers Squibb Company) is a common and effective approach in oncology, particularly in advanced RCC, where such combinations have become a standard of care.
• The development of zanzalintinib, a novel TKI, and its evaluation in pivotal trials for colorectal cancer (CRC), RCC, and NET, positions the company against other TKI developers and broader oncology pipelines. The positive OS results for zanzalintinib in STELLAR-303 (CRC) are a significant achievement, as demonstrating an overall survival benefit is a high bar in oncology clinical trials and can differentiate a therapy in a crowded market. For example, regorafenib, the comparator in STELLAR-303, is an approved therapy for CRC, and zanzalintinib's superiority in OS suggests a potential improvement over existing standards.
• The expansion into biotherapeutics, including ADCs (e.g., XB010, XB371, XB033, XB773) and bispecific antibodies (e.g., XB628), aligns with the industry's shift towards more targeted and potent therapies. Companies like Seagen (now part of Pfizer), AstraZeneca, and Daiichi Sankyo are leaders in ADC development, while companies like Amgen and Regeneron are active in bispecific antibodies. The company's collaborations (e.g., with Catalent for SMARTag technology, Invenra for novel binders) are standard industry practices to leverage specialized expertise and accelerate development.
• The discontinuation of the STELLAR-305 Phase 3 trial in SCCHN due to competitive landscape and other commercial opportunities is a pragmatic decision common in drug development, where companies frequently re-evaluate pipeline assets against evolving market dynamics and competitor pipelines (e.g., Merck's KEYTRUDA in SCCHN).

Legal Proceedings

• Ongoing patent infringement litigation against MSN Pharmaceuticals, Inc. regarding generic versions of CABOMETYX tablets, with an appeal by MSN to the CAFC for certain patents (439, 440, 015) and new litigation for the 039 Patent.
• Ongoing patent infringement litigation against Sun Pharmaceutical Industries Ltd. regarding generic versions of CABOMETYX tablets, with a trial scheduled for November 2, 2026, and new litigation for the 039 Patent.
• Settlement and license agreement with Biocon Pharma Limited, granting Biocon a license to market its generic version of CABOMETYX in the United States beginning January 1, 2031, subject to FDA approval and regulatory review.
• Ongoing patent infringement litigation against Azurity Pharmaceuticals, Inc. regarding its 505(b)(2) New Drug Application for cabozantinib (S)-malate tablets.
• USPTO declined to institute Azurity's inter partes review of the 349 Patent (June 4, 2025) and the 039 Patent (July 2, 2025).

Stakeholder Impact

• Shareholders: Positive impact from strong product revenue growth, increased net income and EPS, positive clinical trial results for zanzalintinib, new regulatory approvals for CABOMETYX, and ongoing share repurchase program. The Biocon settlement provides long-term clarity on generic entry.
• Patients: Potential for new treatment options with the advancement of zanzalintinib and other pipeline candidates, as well as expanded indications for CABOMETYX.
• Employees: Continued investment in R&D and pipeline expansion suggests job stability and growth opportunities. Restructuring expenses were incurred in prior periods, indicating a rebalancing of the workforce.
• Customers (Healthcare Providers/Payers): Expanded treatment options for various cancers with CABOMETYX and potential new therapies. Ongoing discussions regarding drug pricing and reimbursement (IRA, Part D Discount Program) indicate continued pressure on pharmaceutical costs.
• Collaboration Partners (Ipsen, Takeda, Merck, Genentech, Daiichi Sankyo, Sairopa, Adagene, Catalent, Invenra): Continued collaboration on development and commercialization, with financial contributions and shared efforts.

Next Steps

• Discuss STELLAR-303 positive results with regulators with the intention to file a New Drug Application in the U.S.
• Present detailed STELLAR-303 results at a future medical meeting.
• Proceed to the planned final analysis for the dual primary endpoint of OS in the NLM patient population for STELLAR-303.
• Expect top-line results for STELLAR-304 (zanzalintinib in non-clear cell RCC) in the first half of 2026.
• Initiate additional pivotal trials evaluating zanzalintinib across a broad array of future potential indications.
• Initiate a phase 1/2 trial and two phase 3 pivotal trials for zanzalintinib in combination with WELIREG/KEYTRUDA in RCC/SCCHN under the collaboration with Merck.
• Progress up to two new development candidates into preclinical development later in 2025.
• Continue to engage in pipeline expansion initiatives, including acquiring and in-licensing promising investigational oncology assets.
• Apply to CMS each year through 2030 to maintain the small biotech exception under the Inflation Reduction Act.
• Trial in Sun ANDA litigation scheduled for November 2, 2026.

Key Dates

Recommendation

The company demonstrates strong underlying business fundamentals with robust product revenue growth driven by CABOMETYX, a key oncology asset. The significant increase in net income and EPS, coupled with positive Phase 3 clinical trial results for zanzalintinib in colorectal cancer, signals strong pipeline progression and future growth potential. The intent to file a New Drug Application for zanzalintinib is a major catalyst. Strategic regulatory approvals for CABOMETYX in new indications further expand market reach. While collaboration revenues saw a temporary dip due to a non-recurring milestone, this does not reflect a fundamental weakness. The ongoing share repurchase program indicates a commitment to returning value to shareholders, and the favorable tax law change provides a substantial cash benefit. Although ongoing ANDA litigation presents a long-term risk of generic competition, the recent settlement with Biocon provides some clarity on future market dynamics. The company's diversified pipeline and disciplined investment approach position it well for sustained growth in the competitive oncology landscape.

Keywords

Oncology, Cancer Treatment, CABOMETYX, Zanzalintinib, SEC Filing, Financial Results, Clinical Trials, Drug Development, Pharmaceutical, Biotech, Patent Litigation, Share Repurchase, FDA Approval, Regulatory Approval, Renal Cell Carcinoma, Hepatocellular Carcinoma, Neuroendocrine Tumors, Colorectal Cancer, Tyrosine Kinase Inhibitor, Biotherapeutics, Antibody-Drug Conjugates, R&D, Earnings, Revenue, EPS